Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis

Clinical Therapeutics

Volumn 24, Issue 9, 2002, Pages 1414-1425

  Weiss, Lee R ^a  

^a Knox Community Hospital   (United States)

Author keywords

Cefuroxime axetil; Chronic bronchitis; Clarithromycin; Levofloxacin

Indexed keywords

CEFACLOR; CEFIXIME; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; AGED; ANTIMICROBIAL THERAPY; ANXIETY NEUROSIS; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME;

EID: 0036749773     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80045-5     Document Type: Article

References (23)

1. Enright PL, Kronmal RA, Higgins MW, et al. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest. 1994;106:827-834.
2. Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. Vital Health Stat 10. 1998;Oct(199):1-428.
3. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;146:1067-1083.
4. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med. 1991;91(Suppl 6A):87S-92S.
5. Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases. Philadelphia, Pa: WB Saunders; 1992:476-485.
6. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis. 1976;113:465-474.
7. Kayser FH. Changes in the spectrum of organisms causing respiratory tract infections: A review. Postgrad Med J. 1992;68(Suppl 3):S17-S23.
8. Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother. 2001;6:1721-1729.
9. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(Suppl 2):S81-S93.
10. Thabaut A, Meyran M, Sofer L, et al. Interactions of ceftibuten with extended-spectrum beta-lactamases: A bacteriological and enzymatic analysis. Drugs Exp Clin Res. 1994;20:49-54.
11. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
12. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8:1398-1420.
13. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995;273:957-960.
14. Balter MS, Hyland RH, Low D, et al. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can Med Assoc J. 1994;10(Suppl):5-23.
15. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995;108(Suppl 2):43S-52S.
16. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44:501-513.
17. DeAbate CA, Myers D, Henry D, et al. Efficacy and tolerability of once-daily grepafloxacin compared with clarithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Drug Invest. 1999;17:21-31.
18. DeAbate CA, Herman-Gnjidic Z, Aneiro L, et al. Moxifloxacin in acute exacerbations of chronic bronchitis-a bacteriological meta-analysis. Poster presented at: 21st Intemational Congress of Chemotherapy; July 4-7, 1999; Birmingham, United Kingdom. Poster P497.
19. Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther. 1998;20:885-900.
20. Lipsky BA, Unowsky J, Zhang H, et al. Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: Sparfloxacin versus clarithromycin. Clin Ther. 1999;21:954-965.
21. Notario G, Siepman N, Devcich K, Guay DR. Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis. Curr Ther Res Clin Exp. 1993;54:628-640.
22. Skaer TL, Sclar DA, Robison LM. Non-compliance with antihypertensive therapy. Economic consequences. Pharmacoeconomics. 1996;9:1-4.
23. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000; 160:1399-1408.